Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421963 · ClinicalTrials.gov registry record · Phase 3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
A Phase 3 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT04421963: Active Phase 3 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.
NCT04421963 is a Phase 3 study of Breast Cancer and Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 185 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421963, a Phase 3 study of Breast Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
Primary Outcome
Serious adverse events and adverse events of special interest reported until 30 days after the last dose of study drug.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
Other
- Research Site - Leuven
- Research Site - Namur
- Research Site - Rio de Janeiro
- Research Site - Plovdiv
- Research Site - Plovdiv
- Research Site - Sofia
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
- Research Site - Willow Grove
New Jersey
- Research Site - Basking Ridge
- Research Site - Hackensack
New York
- Research Site - New York
- Research Site - The Bronx
Florida
- Research Site - Boca Raton
Maryland
- Research Site - Towson
Michigan
- Research Site - Detroit
Minnesota
- Research Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2027-04-06 |
| Phase | Phase 3 |
What the registry record for NCT04421963 still lists
NCT04421963 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT04421963 names 20 study sites across 11 states, led by Other, Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04421963 about?
NCT04421963 is a clinical study titled "Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib". The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
What is the current status of trial NCT04421963?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2020-08-04. Estimated completion is 2027-04-06.
What conditions does trial NCT04421963 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT04421963?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT04421963?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04421963 being conducted?
This trial has 20 study locations across Florida, Maryland, Michigan, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04421963's enrollment target sits among peer trials
185 397th of 1224 higher than 826 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
- NCT05897424 · 185 participants · Phase 2
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI